Antagonist antibodies and their fab fragments against GPVI and uses thereof
The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab. The invention concerns a method for prevention of platelet activation when an anti-GP VI Fab is used.
1. A method for treating thrombotic or vascular diseases, the method comprising administering to a subject an antibody Fab fragment that specifically binds to human platelet membrane protein Glycoprotein VI (GPVI) and induces a GPVI depletion phenotype, wherein the antibody Fab fragment binds to a conformational epitope of human GPVI and contacts human GPVI amino acid residues Ser 43, Arg 67, and Asp 81.
2. A method treating thrombotic or vascular diseases, the method comprising administering to a subject an engineered Fab fragment comprising a combination of a humanized heavy chain (HC) amino acid sequence and a humanized light chain (LC) amino acid sequence, wherein the humanized heavy chain further comprises a c-terminal extension comprising additional amino acid residues and wherein the c-terminal extension prevents recognition by anti-Fab antibodies, wherein the engineered Fab fragment specifically binds to human platelet membrane protein Glycoprotein VI (GPVI) and induces a GPVI depletion phenotype, and wherein the engineered Fab fragment binds to a conformational epitope of human GPVI and contacts human GPVI amino acid residues Ser 43, Arg 67, and Asp 81.
3. The method of claim 2 , wherein the c-terminal extension is a peptide comprising an amino acid sequence selected from the group consisting of GlyGlyGlyGlySer (SEQ ID NO: 36) and (GlyGlyGlyGlySer) 2 (SEQ ID NO:37).
4. The method of claim 2 , wherein the antibody Fab fragment is humanized.
5. The method of claim 2 , wherein the Fab fragment comprises:
(a) complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) having amino acid sequences defined by SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20; and
(b) complementarity determining regions (CDRs) of a light chain variable region (LCVR) having amino acid sequences defined by SEQ ID NO: 21, SEQ ID NO: 22, and SEQ ID NO: 23; and
wherein at least 2 amino acid residues of each CDR can be changed to another amino acid residue without directly disrupting a contact with a GPVI epitope residue.
6. The method of claim 2 , wherein the Fab fragment comprises a heavy chain of SEQ ID NO.6 and a light chain of SEQ ID NO.8 or sequences having at least 80% identity with these sequences, as long as the antibody Fab fragment binding specificity is maintained.
7. The method of claim 2 , wherein the humanized Fab fragment comprises a combination of a heavy chain variable region (HCVR) amino acid sequence and a light chain variable region (LCVR) amino acid sequence, selected from the group consisting of
(a) LCVR (SEQ ID NO.15) and HCVR (SEQ ID NO.10);
(b) LCVR (SEQ ID NO.15) and HCVR (SEQ ID NO.11);
(c) LCVR (SEQ ID NO.15) and HCVR (SEQ ID NO.12);
(d) LCVR (SEQ ID NO.15) and HCVR (SEQ ID NO.13);
(e) LCVR (SEQ ID NO.15) and HCVR (SEQ ID NO.14);
(f) LCVR (SEQ ID NO.16) and HCVR (SEQ ID NO.11);
(g) LCVR (SEQ ID NO.17) and HCVR (SEQ ID NO.11); and
(h) LCVR (SEQ ID NO.17) and HCVR (SEQ ID NO.13).
8. The method of claim 4 , wherein the c-terminal extension is a peptide comprising an amino acid sequence selected from the group consisting of GlyGlyGlyGlySer (SEQ ID NO: 36) and (GlyGlyGlyGlySer) 2 (SEQ ID NO:37).
9. The method of claim 5 , wherein the c-terminal extension is a peptide comprising an amino acid sequence selected from the group consisting of GlyGlyGlyGlySer (SEQ ID NO: 36) and (GlyGlyGlyGlySer) 2 (SEQ ID NO:37).
10. The method of claim 6 , wherein the c-terminal extension is a peptide comprising an amino acid sequence selected from the group consisting of GlyGlyGlyGlySer (SEQ ID NO: 36) and (GlyGlyGlyGlySer) 2 (SEQ ID NO:37).
11. The method of claim 7 , wherein the c-terminal extension is a peptide comprising an amino acid sequence selected from the group consisting of GlyGlyGlyGlySer (SEQ ID NO: 36) and (GlyGlyGlyGlySer) 2 (SEQ ID NO:37).
12. The method of claim 1 , wherein the antibody Fab fragment is humanized.
13. The method of claim 1 , wherein the Fab fragment comprises:
(a) complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) having amino acid sequences defined by SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20; and
(b) complementarity determining regions (CDRs) of a light chain variable region (LCVR) having amino acid sequences defined by SEQ ID NO: 21, SEQ ID NO: 22, and SEQ ID NO: 23; and
wherein at least 2 amino acid residues of each CDR can be changed to another amino acid residue without directly disrupting a contact with a GPVI epitope residue.
14. The method of claim 1 , wherein the Fab fragment comprises a heavy chain of SEQ ID NO.6 and a light chain of SEQ ID NO.8 or sequences having at least 80% identity with these sequences, as long as the antibody Fab fragment binding specificity is maintained.
15. The method of claim 1 , wherein the Fab fragment comprises a combination of a heavy chain variable region (HCVR) amino acid sequence and a light chain variable region (LCVR) amino acid sequence, selected from the group consisting of
(a) LCVR (SEQ ID NO.15) and HCVR (SEQ ID NO.10);
(b) LCVR (SEQ ID NO.15) and HCVR (SEQ ID NO.11);
(c) LCVR (SEQ ID NO.15) and HCVR (SEQ ID NO.12);
(d) LCVR (SEQ ID NO.15) and HCVR (SEQ ID NO.13);
(e) LCVR (SEQ ID NO.15) and HCVR (SEQ ID NO.14);
(f) LCVR (SEQ ID NO.16) and HCVR (SEQ ID NO.11);
(g) LCVR (SEQ ID NO.17) and HCVR (SEQ ID NO.11); and
(h) LCVR (SEQ ID NO.17) and HCVR (SEQ ID NO.13).